CytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
CYTODYN INC (CYDY)
NASDAQ:AMEX Investor Relations:
ir.cytodyn.com
Company Research
Source: GlobeNewswire
VANCOUVER, Washington, Sept. 16, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced it has been selected for a poster and an oral presentation at the upcoming AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity, taking place September 24 to 27, 2025, in Montreal, Canada. Richard Pestell, M.D., Ph.D., FRCP, AO, Lead Consultant in Preclinical and Clinical Oncology at CytoDyn, will deliver a podium presentation on the effects of leronlimab on metastatic triple-negative breast cancer. “We are encouraged by these findings, which suggest that leronlimab may convert ‘cold’ tumors into ‘hot’ ones, making them more respo
Show less
Read more
Impact Snapshot
Event Time:
CYDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYDY alerts
High impacting CYTODYN INC news events
Weekly update
A roundup of the hottest topics
CYDY
News
- CytoDyn Announces Resolution of Class Action Lawsuit [Yahoo! Finance]Yahoo! Finance
- CytoDyn Announces Resolution of Class Action LawsuitGlobeNewswire
- CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer SymposiumGlobeNewswire
- CytoDyn Secures $30 Million Commitment from Yorkville AdvisorsGlobeNewswire
- Halper Sadeh LLC Encourages CytoDyn Inc. Shareholders to Contact the Firm to Discuss Their RightsBusiness Wire
CYDY
Sec Filings
- 12/3/25 - Form EFFECT
- 12/2/25 - Form 424B3
- 12/1/25 - Form 8-K
- CYDY's page on the SEC website